



Press release from Emotra AB (publ)
Göteborg, October 7, 2020

Emotra announces the exercise price for subscription warrants in the TO 2020 rights issue

On October 6, 2020, Emotra AB (“Emotra” or “the Company”) established the exercise price for subscription warrants in the TO 2020 rights issue (“the Subscription warrants”). The exercise price has been set to 0.40 SEK per new share purchased through the use of subscription warrants.

The issuing costs are estimated to amount to approximately 0.2 MSEK. If fully utilised, the subscription warrant conversion will provide the Company with approximately 4.6 MSEK before issuing costs.

Terms and conditions for Subscription warrants

Terms and conditions: one (1) subscription warrant allows the shareholder to purchase one (1) new share.

Exercise price: 0.40 SEK per share; not subject to brokerage.

Exercise period: October 9 to October 23 inclusive, 2020.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail:

daniel@emotra.se

Fel! Hittar inte referenskälla.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1,
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se